Internal Medicine, Medical Oncology · Mobile, AL
NPI
1538112701
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
3719 Dauphin Street, 5th Floor
Mobile, AL, 36608
Phone (251) 625-6896
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.7M
104,370 services
Medicare patients, 2024
468
Average age 76
Drug cost, 2024
$3.6M
1,350 prescriptions
Company payments, 2025
$2,150
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael W Meshad was code J9271 (injection, pembrolizumab, 1 mg), 20,800 times for 16 patients. In total Michael W Meshad billed 104,370 services in 134 codes, and Medicare paid $2.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 20,800 | 16 | $44.59 | $928K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 6,450 | 11 | $0.09 | $590 |
| J0897 Injection, denosumab, 1 mg | Office | 2,100 | 16 | $20.45 | $43K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 799 | 23 | $0.08 | $66.26 |
| 36415 Venipuncture Blood Collection | Office | 649 | 221 | $8.65 | $5,614 |
| 85025 Blood Count | Office | 625 | 217 | $7.58 | $4,736 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 556 | 12 | $0.07 | $40.46 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 550 | 13 | $0.64 | $354 |
| 80053 Clinical Chemistry | Office | 494 | 204 | $10.31 | $5,094 |
| 99213 Office E&M - Established | Office | 425 | 224 | $59.24 | $25K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 355 | 212 | $11.87 | $4,213 |
| 96413 Chemotherapy Administration | Office | 230 | 57 | $83.67 | $19K |
| 99214 Office E&M - Established | Office | 218 | 125 | $89.98 | $20K |
| 96367 Intravenous Infusion, Hydration | Office | 208 | 34 | $18.12 | $3,769 |
| 96372 Injection Administration | Office | 191 | 65 | $9.77 | $1,866 |
By year: 2022 $2.2M for 90,542 services; 2023 $3.1M for 117,289 services; 2024 $2.7M for 104,370 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 649 | 221 | $8.65 | $5,614 |
| 85025 Blood Count | 625 | 217 | $7.58 | $4,736 |
| 80053 Clinical Chemistry | 494 | 204 | $10.31 | $5,094 |
| 82784 Immunoassay | 132 | 20 | $9.11 | $1,203 |
| 84443 Clinical Chemistry | 96 | 21 | $16.46 | $1,580 |
| 84439 Clinical Chemistry | 95 | 20 | $8.84 | $840 |
| 86300 Immunoassay | 83 | 58 | $20.17 | $1,674 |
| 83521 Immunoassay | 59 | 15 | $16.92 | $999 |
| 82378 Clinical Chemistry | 30 | 13 | $18.58 | $557 |
| 82728 Clinical Chemistry | 27 | 18 | $13.36 | $361 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael W Meshad prescribed most often to Medicare patients was Letrozole, with 214 prescriptions and refills. In total Michael W Meshad wrote 1,350 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 214 | 446 | 48 | $4,601 |
| Anastrozole Generic | 89 | 191 | 24 | $1,387 |
| Prednisone Generic | 55 | 55 | 12 | $145 |
| Brukinsa Zanubrutinib | 54 | 54 | Under 11 | $736K |
| Hydroxyurea Generic | 54 | 76 | Under 11 | $730 |
| Abiraterone Acetate Generic | 53 | 53 | Under 11 | $157K |
| Ondansetron Hcl Generic | 50 | 59 | 28 | $858 |
| Dexamethasone Generic | 39 | 52 | 22 | $894 |
| Trazodone Hcl Generic | 38 | 44 | 13 | $106 |
| Calquence Acalabrutinib Maleate | 36 | 36 | Under 11 | $455K |
| Tamoxifen Citrate Generic | 33 | 86 | Under 11 | $1,423 |
| Levothyroxine Sodium Generic | 28 | 42 | Under 11 | $124 |
| Imbruvica Ibrutinib | 27 | 27 | Under 11 | $429K |
| Prochlorperazine Maleate Generic | 26 | 26 | 17 | $478 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 24 | 24 | 17 | $508 |
Brand drugs: 274 claims; generic drugs: 1,076 claims; opioid claims: 50.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael W Meshad $2,150 ($2,150 in general payments such as food, travel and fees) from 41 companies. The largest payer was Novartis Pharmaceuticals Corporation with $337.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 16 | $337 |
| Celgene Corporation BMY | 7 | $169 |
| Janssen Biotech, Inc. JNJ | 9 | $155 |
| Merck Sharp & Dohme LLC MRK | 6 | $133 |
| Eisai Inc. 4523.T | 5 | $103 |
| SpringWorks Therapeutics, Inc. | 6 | $102 |
| GlaxoSmithKline, LLC. GSK | 5 | $91.43 |
| Pfizer Inc. PFE | 5 | $82.17 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $70.71 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 3 | $69.85 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.